These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 16312829)

  • 1. Mitoxantrone and prednimustine combination chemotherapy in breast cancer.
    Kaufmann M; Schmid H; Raeth U
    J Chemother; 1989 Jul; 1(4 Suppl):1191-3. PubMed ID: 16312829
    [No Abstract]   [Full Text] [Related]  

  • 2. Mitoxantrone: mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity.
    Lenk H; Müller U; Tanneberger S
    Anticancer Res; 1987; 7(6):1257-64. PubMed ID: 3327453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Combined mitoxantrone therapy for heavily pretreated metastatic breast cancer].
    Yokoe T; Iino Y; Aoyagi H; Maemura M; Sugamata N; Takai Y; Horiguchi J; Ishida T; Morishita Y
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):169-71. PubMed ID: 8422183
    [No Abstract]   [Full Text] [Related]  

  • 4. Mitoxantrone.
    Med Lett Drugs Ther; 1988 Jul; 30(769):67-8. PubMed ID: 3380059
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study.
    Barnadas A; Mendiola C; Casado A; Villar A; Jimeno J; Clerigue M; Rosell R; Diaz-Rubio E; Cortés-Funes H; García de Paredes M
    Eur J Cancer; 1997 Feb; 33(2):312-5. PubMed ID: 9135508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prednimustine, methotrexate, 5-fluorouracil, mitoxantrone and tamoxifen for advanced breast cancer in postmenopausal women. A phase II trial.
    Andersson M; Mouridsen HT
    Acta Oncol; 1988; 27(3):235-9. PubMed ID: 3415852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of adjuvant chemotherapy cyclophosphamide, mitoxantrone, and fluorouracil in women with breast cancer.
    Kumpulainen EJ; Hirvikoski PP; Johansson RT
    Acta Oncol; 2008; 47(1):120-3. PubMed ID: 18097780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.
    Toledano A; Azria D; Garaud P; Fourquet A; Serin D; Bosset JF; Miny-Buffet J; Favre A; Le Floch O; Calais G
    J Clin Oncol; 2007 Feb; 25(4):405-10. PubMed ID: 17264336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen versus tamoxifen + mitoxantrone treatment in metastatic breast cancer.
    Kars A; Baltali E; Tekuzman G; Firat D; Alakavuklar M
    J Chemother; 1989 Jul; 1(4 Suppl):1196-7. PubMed ID: 16312831
    [No Abstract]   [Full Text] [Related]  

  • 10. Mitoxantrone-cyclophosphamide-fluorouracil-combination chemotherapy in metastatic breast cancer. 3-Year-follow-up.
    Büyükünal E; Derman U; Serdengeçti S; Berkarda B
    J Chemother; 1989 Jul; 1(4 Suppl):1201-2. PubMed ID: 16312833
    [No Abstract]   [Full Text] [Related]  

  • 11. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.
    Rouëssé J; de la Lande B; Bertheault-Cvitkovic F; Serin D; Graïc Y; Combe M; Leduc B; Lucas V; Demange L; Nguyen TD; Castèra D; Krzisch C; Villet R; Mouret-Fourme E; Garbay JR; Noguès C;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1072-80. PubMed ID: 16504757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitozantrone and prednimustine in the treatment of advanced breast cancer--a toxic regimen with low activity.
    O'Brien ME; Eccles DM; Allen SG; Knight G; Rodger A; Chetty U; Smyth JF; Leonard RC
    Cancer Chemother Pharmacol; 1991; 28(5):402-4. PubMed ID: 1914086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the hormonal treatment of breast cancer.
    Boughey JC; Buzdar AU; Hunt KK
    Curr Probl Surg; 2008 Jan; 45(1):13-55. PubMed ID: 18206436
    [No Abstract]   [Full Text] [Related]  

  • 14. High risk of therapy-related leukemia and preleukemia after therapy with prednimustine, methotrexate, 5-fluorouracil, mitoxantrone, and tamoxifen for advanced breast cancer.
    Andersson M; Philip P; Pedersen-Bjergaard J
    Cancer; 1990 Jun; 65(11):2460-4. PubMed ID: 2337861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
    Conti F; Carpano S; Sergi D; Di Lauro L; Amodio A; Vici P; Abbate MI; Ferranti FR; Viola G; Botti C; Foggi P; Sperduti I; Lopez M
    Clin Ter; 2007; 158(4):331-41. PubMed ID: 17953285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Average relative dose intensity and the impact on design of clinical trials.
    Hryniuk WM
    Semin Oncol; 1987 Mar; 14(1):65-74. PubMed ID: 3823917
    [No Abstract]   [Full Text] [Related]  

  • 17. Ixabepilone (Ixempra) for breast cancer.
    Med Lett Drugs Ther; 2008 Jan; 50(1278):7-8. PubMed ID: 18219261
    [No Abstract]   [Full Text] [Related]  

  • 18. Leukaemia due to mitoxantrone.
    Prescrire Int; 2007 Aug; 16(90):153-6. PubMed ID: 17724842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer.
    Gennari A; Amadori D; De Lena M; Nanni O; Bruzzi P; Lorusso V; Manzione L; Conte PF
    J Clin Oncol; 2006 Aug; 24(24):3912-8. PubMed ID: 16921042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
    Tamura K
    Rinsho Ketsueki; 2009 Apr; 50(4):276-81. PubMed ID: 19404020
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.